Πρόσφατες δημοσιεύσεις στο περιοδικό The Lancet HIV

Dolutegravir–rilpivirine for virological suppression

One of the remaining issues in HIV therapeutics is whether, in the era of potent integrase inhibitors with a high genetic barrier to resistance, one or two companion drugs is needed for durable efficacy. Thus, the 48-week results of the SWORD-1 and SWORD-2 trials were big news in HIV treatment.1 For the first time, a nucleoside-sparing and nucleotide-sparing unboosted regimen, comprising dolutegravir and rilpivirine only, matched the efficacy of triple therapy for maintenance of virological suppression in a large randomised clinical trial.

Have clinical trials in HIV finally matured?

HIV is one of the most studied areas of infectious diseases. However, most trials evaluating treatments have been done in predominantly first-line patients and typically use a standard two-group inefficient design.1 Two-group designs are inefficient because they fail to share control groups and rarely consider comparisons with other leading treatments.2 The number of trials and size of included populations drops dramatically as the disease becomes differentiated, such as second-line and third-line treatments or coinfections.

Drug interactions: not just for orally administered drugs

Although the first hormonal contraceptive, an oral pill, was approved by the US Food and Drug Administration in 1960, substantial gaps remain in the understanding of progestin pharmacokinetics, dose-responses, and drug-drug interactions. In The Lancet HIV, Kimberly K Scarsi and colleagues1 report results of an important drug-drug interaction study investigating concomitant use of a vaginally administered combined hormonal contraceptive ring (containing ethinyl estradiol and etonogestrel) and orally administered antiretroviral therapy (containing either efavirenz or ritonavir-boosted atazanavir).

About us

Στο, φιλοξενούμε αφιλοκερδώς το "Πρόγραμμα Συνεργασίας" Μονάδων Λοιμώξεων για την ανάπτυξη διαδικτυακής τράπεζας κλινικών παραμέτρων. Το Πρόγραμμα δημιουργήθηκε από έναν γιατρό ειδικό στην HIV λοίμωξη με τη συμμετοχή των Μονάδων: Περισσότερα

% Αναπηρία και HIV

Νέος κανονισμός

Ενιαίος Πίνακας Προσδιορισμού Ποσοστού Αναπηρίας


@ Διαύγεια


διαφάνεια στο κράτος

Διαδικτυακές αναρτήσεις διοικητικών αποφάσεων για το HIV/AIDS


Σας έχει σπάσει ποτέ το προφυλακτικό κατά τη διάρκεια μιας ερωτικής επαφής;
Δεν χρησιμοποιώ




Χρήσιμες πληροφορίες

Τηλεφωνική γραμμή για το HIV/AIDS


Δευτέρα - Παρασκευή
09:00 - 21:00